1) WHO summary report (2020). https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports accessed on 29th March, 2020.
2) World Health Organization. WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020.
3) https://www.who.int/emergencies.arcgis.com/experience accessed on 29th March, 2020.
4) Tyrrell D.A., Bynoe M.L. Cultivation of viruses from a high proportion of patients with colds. Lancet, 1: 76–77(1966).
5) GISAID Global Initiative on Sharing All Influenza Data. Phylogeny of SARS-like betacoronaviruses including novel coronavirus (nCoV). https://nextstrain.org/groups/blab/sars-like-cov) (2020).
6) Zhou P., Yang X., Wang X., et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature , 579: 270–273. https://doi.org/10.1038/s41586-020-2012-7.
7) Rottier P.J.M. The Coronavirus Membrane Glycoprotein. In: Siddell S.G. (eds) The Coronaviridae. The Viruses. Springer, Boston, MA. (1995). https://link.springer.com/chapter/10.1007/978-1-4899-1531-3_6#citeas
8) Zhu N., Zhang D., Wang W., et al. A novel coronavirus from patients with pneumonia in China, 2019 N Engl J Med, (2020). https://www.nejm.org/doi/full/10.1056/NEJMoa2001017
9) Wu F., Zhao S., Yu B., et al A new coronavirus associated with human respiratory disease in China. Nature, Feb 3. (2020). https://doi.org/10.1038/s41586-020-2008-3
10) Lam CW., Chan M.H., Wong C.K., Severe acute respiratory syndrome: clinical and laboratory manifestations. Clin Biochem Rev, 25:121-132. (2004). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1904416/
11) Azhar E., Hui D.S.C., Memish Z.A., Drosten C., Zumla A., The Middle East Respiratory Syndrome (MERS). Infect Dis Clin North Am, 33:891-905(2019). https://www.ijidonline.com/article/S1201-9712(20)30011-4/pdf
12) Ranicello (2020) http://www.virology.ws/2020/02/13/furin-cleavage-site-in-the-
sars- cov-2-coronavirus-glycoprotein/.
13) Ed Yong, (2020) www.msn.com/en-gb/news/world/why-the-coronavirus.
14) Xia S., Zhu Y., Liu M., Fusion mechanism of 2019-nCoV and fusion inhibitors
targeting HR1 domain in spike protein. Cell Mol Immunol, (2020). https://www.nature.com/articles/s41423-020-0374-2
15) Prompetchara E., Ketloy C., Palaga T. Immune responses in COVID- 19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol, (2020). https://www.ncbi.nlm.nih.gov/pubmed/32105090.
16) Walls et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell , (2020). https://doi.org/10.1016/j.cell.2020.02.058
17) Millet, J. K. and Whittaker G. R. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc. Natl. Acad. Sci. USA , 111:15214–15219. (2014). https://www.ncbi.nlm.nih.gov/pubmed/25288733
18) Belouzard S., Chu V. C. and Whittaker G. R. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc. Natl. Acad. Sci. USA. , 106:5871–5876. (2009). https://www.pnas.org/content/106/14/5871
19) Kirchdoerfer, R. N., Cottrell C. A., Wang N., Pallesen et al Pre-fusion structure of a human coronavirus spike protein. Nature, 531: 118–121(2016). https://www.ncbi.nlm.nih.gov/pubmed/26935699
20) Neeltje van D., Trenton B., Dylan H. M., Myndi e tal. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 .New England Journal of Medicine (Letter to Editor). (2020). https://www.nejm.org/doi/pdf/10.1056/NEJMc2004973?articleTools=true
21) Zhang H., Penninger J. M., Li Y, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med , .(2020). https://doi.org/10.1007/s00134-020-05985-9.
22) Dales, N A et al Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. J. Am. Chem. Soc, 124: 11852–11853. (2002). https://www.ncbi.nlm.nih.gov/pubmed/12358520
23) Roncati L., Graziana G., Antonio M., Beniamino P. Medical Hypotheses 140 109686(2020). https://doi.org/10.1016/j.mehy.2020.109686 .
24) Boehm M., Nabel E. G. Angiotensin-converting enzyme 2–a new cardiac regulator. N Engl J Med. 347 (22): 1795–7. (2002).https://www.ncbi.nlm.nih.gov/pubmed?cmd=link&linkname=pubmed_pubmed&uid=12075344,12456857.
25) Huang M. L., Li X., Meng Y., et al Upregulation of angiotensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors. Clin Exp Pharmacol Physiol, 37(1):1–6. (2010). https://www.ncbi.nlm.nih.gov/pubmed/19793108
26) Ferrario C. M., Jessup J., Chappell M. C., et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin- converting enzyme 2. Circulation . 111(20):2605–10. (2005).
https://www.ahajournals.org/doi/full/10.1161/circulationaha.104.510461
27) Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med, 8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11. (2020).
28) Jaaks P. and Bernsconi M. The proproteinconvertasefurin in tumour progression Int J of Cancer ,141(4):654-663. (2017). https://www.ncbi.nlm.nih.gov/pubmed/28369813
29) Couture F., Kwiatkowska A., Dory Y L., Day R. Therapeutic uses of furin and its inhibitors: a patent review. Expert Opin Ther Pat, 25(4):379-96. (2015). doi: 10.1517/13543776.2014.1000303.Epub 2015 Jan 7. https://www.ncbi.nlm.nih.gov/pubmed/25563687.